Get to know our clinical trials
Placebo-controlled, parallel-group clinical trial to verify the benefit of aducanumab in participants with Alzheimer's disease.
THE GOAL OF THE TRIAL IS TO SEE IF ADUCANUMAB (ADUHELMTM, ALSO KNOWN AS BIIB037, THE TRIAL DRUG) CAN HELP SLOW THE DEVELOPMENT OF AD (ALZHEIMER'S DISEASE) SYMPTOMS IN PEOPLE WITH EARLY AD.
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- PHASE IIIB/IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO VERIFY THE CLINICAL BENEFIT OF ADUCANUMAB (BIIB037) IN PARTICIPANTS WITH ALZHEIMER'S DISEASE.
- Code EudraCT: .
- Protocol number: 221AD305
- Promoter: Biogen
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.